80 related articles for article (PubMed ID: 32732678)
1. Marginal Zone Lymphomas.
Bertoni F; Rossi D; Raderer M; Zucca E
Cancer J; 2020; 26(4):336-347. PubMed ID: 32732678
[TBL] [Abstract][Full Text] [Related]
2. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F
Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598
[TBL] [Abstract][Full Text] [Related]
3. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
Lue JK; O'Connor OA; Bertoni F
Ann Lymphoma; 2020 Sep; 4():7. PubMed ID: 34667996
[TBL] [Abstract][Full Text] [Related]
4. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
Walewska R; Eyre TA; Barrington S; Brady J; Fields P; Iyengar S; Joshi A; Menne T; Parry-Jones N; Walter H; Wotherspoon A; Linton K;
Br J Haematol; 2024 Jan; 204(1):86-107. PubMed ID: 37957111
[No Abstract] [Full Text] [Related]
5. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Denlinger NM; Epperla N; William BM
Cancer Manag Res; 2018; 10():615-624. PubMed ID: 29628774
[TBL] [Abstract][Full Text] [Related]
6. Management of marginal zone lymphomas.
Merli M; Arcaini L
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):676-687. PubMed ID: 36485086
[TBL] [Abstract][Full Text] [Related]
7. A roadmap for clinical trial design in marginal zone lymphoma.
Alderuccio JP; Habermann T; Kuker R; Moskowitz CH; Zelenetz AD; Lossos IS
Am J Hematol; 2022 Nov; 97(11):1398-1403. PubMed ID: 36030403
[TBL] [Abstract][Full Text] [Related]
8. How do you define treatment success in MZL?
Casulo C
Blood; 2024 Feb; 143(5):382-383. PubMed ID: 38300612
[No Abstract] [Full Text] [Related]
9. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A; de Vos S; Coleman M; Martin P; Flowers CR; Thieblemont C; Morschhauser F; Collins GP; Ma S; Peles S; Smith SD; Barrientos JC; Chong E; Wu S; Cheung LW; Kwei K; Hauns B; Arango-Hisijara I; Chen R
Blood Adv; 2020 Nov; 4(22):5773-5784. PubMed ID: 33227125
[TBL] [Abstract][Full Text] [Related]
10. Marginal zone lymphomas.
Zucca E; Rossi D; Bertoni F
Hematol Oncol; 2023 Jun; 41 Suppl 1():88-91. PubMed ID: 37294969
[TBL] [Abstract][Full Text] [Related]
11. Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F; Bruscaggin A; Guidetti F; Terzi di Bergamo L; Faderl M; Spina V; Condoluci A; Bonomini L; Forestieri G; Koch R; Piffaretti D; Pini K; Pirosa MC; Cittone MG; Arribas A; Lucioni M; Ghilardi G; Wu W; Arcaini L; Baptista MJ; Bastidas G; Bea S; Boldorini R; Broccoli A; Buehler MM; Canzonieri V; Cascione L; Ceriani L; Cogliatti S; Corradini P; Derenzini E; Devizzi L; Dietrich S; Elia AR; Facchetti F; Gaidano G; Garcia JF; Gerber B; Ghia P; Gomes da Silva M; Gritti G; Guidetti A; Hitz F; Inghirami G; Ladetto M; Lopez-Guillermo A; Lucchini E; Maiorana A; Marasca R; Matutes E; Meignin V; Merli M; Moccia A; Mollejo M; Montalban C; Novak U; Oscier DG; Passamonti F; Piazza F; Pizzolitto S; Rambaldi A; Sabattini E; Salles G; Santambrogio E; Scarfò L; Stathis A; Stüssi G; Geyer JT; Tapia G; Tarella C; Thieblemont C; Tousseyn T; Tucci A; Vanini G; Visco C; Vitolo U; Walewska R; Zaja F; Zenz T; Zinzani PL; Khiabanian H; Calcinotto A; Bertoni F; Bhagat G; Campo E; De Leval L; Dirnhofer S; Pileri SA; Piris MA; Traverse-Glehen A; Tzankov A; Paulli M; Ponzoni M; Mazzucchelli L; Cavalli F; Zucca E; Rossi D
Blood; 2022 Feb; 139(5):732-747. PubMed ID: 34653238
[TBL] [Abstract][Full Text] [Related]
12. New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas.
Donzel M; Baseggio L; Fontaine J; Pesce F; Ghesquières H; Bachy E; Verney A; Traverse-Glehen A
Curr Oncol; 2021 Sep; 28(5):3430-3447. PubMed ID: 34590593
[TBL] [Abstract][Full Text] [Related]
13. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.
Vela V; Juskevicius D; Dirnhofer S; Menter T; Tzankov A
Virchows Arch; 2022 Feb; 480(2):403-413. PubMed ID: 34494161
[TBL] [Abstract][Full Text] [Related]
16. How do we sequence therapy for marginal zone lymphomas?
Broccoli A; Zinzani PL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):295-305. PubMed ID: 33275704
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics, treatment patterns, and survival outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma in the United States.
Lin H; Li Z; Wu Y; Wang H
Am J Transl Res; 2023; 15(6):4357-4368. PubMed ID: 37434848
[TBL] [Abstract][Full Text] [Related]
18. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
Guidetti F; Arribas AJ; Sartori G; Spriano F; Barnabei L; Tarantelli C; Von Roemeling R; Martinez E; Zucca E; Bertoni F
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675328
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous premature termination in zinc-finger domain of Krüppel-like factor 2 gene associates with dysregulated immunity.
Pernaa N; Keskitalo S; Chowdhury I; Nissinen A; Glumoff V; Keski-Filppula R; Junttila J; Eklund KK; Santaniemi W; Siitonen S; Seppänen MR; Vähäsalo P; Varjosalo M; Åström P; Hautala T
Front Immunol; 2022; 13():819929. PubMed ID: 36466816
[TBL] [Abstract][Full Text] [Related]
20. Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance.
Liu S; Yang P; Wang L; Li C; Zhang W; Wang J; Jing H
Ann Transl Med; 2022 Oct; 10(20):1105. PubMed ID: 36388812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
